# Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery

> **NCT01537107** · PHASE1 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 31 (actual)

## Conditions studied

- Acinar Cell Adenocarcinoma of the Pancreas
- Duct Cell Adenocarcinoma of the Pancreas
- Recurrent Pancreatic Cancer
- Stage IV Pancreatic Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** vismodegib
- **DRUG:** sirolimus
- **PROCEDURE:** positron emission tomography
- **PROCEDURE:** computed tomography
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis
- **RADIATION:** fludeoxyglucose F 18

## Key facts

- **NCT ID:** NCT01537107
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03-05
- **Primary completion:** 2018-06-27
- **Final completion:** 2018-06-27
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2019-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01537107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01537107, "Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01537107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*